Company / SG&A Expense
Moderna SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.0B
FY2025
5-year range
$110.0M / $1.5B
FY2021-FY2025
Trend
-13.3%
vs FY2024
Sector context
#24 of 213
Health Care
What the data says
Moderna's sg&a expense of $1.0B is higher than 89% of companies in the Health Care sector (FY2025). SG&A Expense has fluctuated over the past 10 years, ranging from $57M in FY2016 to $1.5B in FY2023.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of +40.2%. Top quartile in the Health Care sector.
Improved from $1.5B to $1.0B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +75.6%
- 5-Year CAGR
- +40.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 213This company $1.0B Sector average $722.3M
▼
+40.9% above sector average
Key checks
Key Insights
- 5-year CAGR of +40.2%, indicating consistent growth.
- In FY2025, sg&a expense decreased 13.3% year-over-year.
- Ranks #24 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | -13.3% |
| FY2024 | $1.2B | -24.2% |
| FY2023 | $1.5B | +723.9% |
| FY2022 | $188.0M | +70.9% |
| FY2021 | $110.0M | -41.5% |
| FY2020 | $188.0M | +70.9% |
| FY2019 | $110.0M | +16.7% |
| FY2018 | $94.3M | +45.6% |
| FY2017 | $64.7M | +12.7% |
| FY2016 | $57.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026